

¹Southern California Clinical Research, Santa Ana and Harbor University of California Los Angeles, CA, USA; ²Department of Dermatology, China-Japan Friendship Hospital, Beijing, China; ³Innovaderm Research, Montréal, QC, Canada; ⁴Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁵Ramón y Cajal University Hospital and Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain; ⁶University Hospital Frankfurt am Main, Frankfurt am Main, Germany; ⁷Oregon Dermatology and Research Center, Portland, OR, USA; ⁸Dermatology Research Institute, Calgary, AB, Canada; ⁹Proby Medical Research, Calgary, AB, Canada; ¹⁰Skin Health & Wellness Centre, Calgary, AB, Canada; ¹¹Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada; ¹²Section of Community Pediatrics, Department of Pediatrics, Calgary, AB, Canada; ¹³Section of Pediatric Rheumatology, Department of Pediatrics, Calgary, AB, Canada; ¹⁴Johnson & Johnson, Spring House/Horsham, PA, USA; ¹⁵St. John's Institute of Dermatology, Guy's & St. Thomas' NHS Foundation Trust and King's College London, London, UK

Data shown are mean (SD), unless otherwise noted. ^aConventional nonbiologic systemics, novel nonbiologic systemics, 125-vitamin D3 and analogues, phototherapy, and biologics. ^bAdalimumab, alefacept, briakinumab, brodalumab, certalizumab pego, efalizumab, etanercept, guselkumab, infliximab, ixekizumab, natalizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab. **BMI**=body mass index, **PUVA**=psoralen plus ultraviolet A, **SD**=standard deviation, **UVB**=ultraviolet B.

Nominal ^{†††} $p < 0.001$ vs PBO^c

*P-values based on Cochran-Mantel-Haenszel chi-square test stratified by geographic region. **IGA 0/1**=IGA score 0/1 & ≥ 2 -grade improvement from baseline.
